Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
MGX
Upturn stock ratingUpturn stock rating

Metagenomi, Inc. Common Stock (MGX)

Upturn stock ratingUpturn stock rating
$1.48
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: MGX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $12.8

1 Year Target Price $12.8

Analysts Price Target For last 52 week
$12.8Target price
Low$1.23
Current$1.48
high$5.5

Analysis of Past Performance

Type Stock
Historic Profit 0%
Avg. Invested days 0
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 54.58M USD
Price to earnings Ratio -
1Y Target Price 12.8
Price to earnings Ratio -
1Y Target Price 12.8
Volume (30-day avg) 7
Beta -
52 Weeks Range 1.23 - 5.50
Updated Date 06/30/2025
52 Weeks Range 1.23 - 5.50
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.85

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -172.21%
Operating Margin (TTM) -674.1%

Management Effectiveness

Return on Assets (TTM) -15.37%
Return on Equity (TTM) -31.93%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -125834573
Price to Sales(TTM) 1.21
Enterprise Value -125834573
Price to Sales(TTM) 1.21
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 37381500
Shares Floating 23232225
Shares Outstanding 37381500
Shares Floating 23232225
Percent Insiders 28.2
Percent Institutions 26.49

Analyst Ratings

Rating 3
Target Price 12.8
Buy 2
Strong Buy 4
Buy 2
Strong Buy 4
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Metagenomi, Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

Metagenomi, Inc. is a gene editing company founded in 2018, pioneering a data-driven approach to discover and develop novel gene editing tools derived from uncultivated microbes. Their focus is on advancing the field of gene therapy through innovative enzymes.

business area logo Core Business Areas

  • Gene Editing Technology: Discovery and development of novel gene editing tools, including CRISPR systems, using metagenomics and computational biology.
  • Therapeutic Development: Applying gene editing technologies to develop therapeutic candidates for various diseases, including genetic disorders.
  • Partnerships and Licensing: Establishing collaborations with pharmaceutical and biotechnology companies for the development and commercialization of gene editing therapies.

leadership logo Leadership and Structure

Brian C. Roberts is the CEO. The organizational structure includes research & development, therapeutic development, and business development teams.

Top Products and Market Share

overview logo Key Offerings

  • Novel Gene Editing Enzymes: Metagenomi's primary offering is its library of novel gene editing enzymes discovered through metagenomics. Market share is still nascent as they are in the development and pre-clinical stages. Competitors include CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), and Intellia Therapeutics (NTLA).
  • Therapeutic Programs: Metagenomi is developing therapeutic programs targeting various genetic diseases. These programs are currently in pre-clinical or early clinical stages, so market share data is not yet available. Competitors include companies developing gene therapies for similar indications.

Market Dynamics

industry overview logo Industry Overview

The gene editing industry is rapidly growing, driven by advances in CRISPR technology and the potential to cure genetic diseases. The market is competitive, with numerous companies developing and commercializing gene editing tools and therapies.

Positioning

Metagenomi is positioned as a leader in the discovery and development of novel gene editing enzymes through its unique metagenomics approach. Their competitive advantage lies in the potential for improved efficacy and safety compared to existing gene editing technologies.

Total Addressable Market (TAM)

The total addressable market for gene editing is estimated to reach tens of billions of dollars in the coming years. Metagenomi is positioned to capture a significant share of this market through its innovative technology and strategic partnerships.

Upturn SWOT Analysis

Strengths

  • Novel gene editing technology
  • Unique metagenomics approach
  • Strong intellectual property portfolio
  • Experienced management team

Weaknesses

  • Early-stage development
  • Limited clinical data
  • High R&D costs
  • Dependence on partnerships

Opportunities

  • Expanding therapeutic pipeline
  • Strategic partnerships and licensing agreements
  • Advancements in gene editing technology
  • Growing market demand for gene therapies

Threats

  • Competition from established gene editing companies
  • Regulatory hurdles
  • Clinical trial failures
  • Ethical concerns related to gene editing

Competitors and Market Share

competitor logo Key Competitors

  • CRISPR Therapeutics (CRSP)
  • Editas Medicine (EDIT)
  • Intellia Therapeutics (NTLA)

Competitive Landscape

Metagenomi is well-positioned with novel technology, but faces competition from more established players in the gene editing space with more advanced clinical programs.

Major Acquisitions

Inscripta, Inc (Strategic Collaboration Not an Acquisition)

  • Year: 2024
  • Acquisition Price (USD millions): 0
  • Strategic Rationale: Multi-target discovery collaboration to identify novel CRISPR systems. No acquisition price since its a collaboration.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by research and development progress, patent filings, and partnership announcements.

Future Projections: Future growth is expected to be driven by the advancement of therapeutic programs into clinical trials and the signing of strategic partnerships.

Recent Initiatives: Recent initiatives include expansion of the gene editing enzyme library and advancement of lead therapeutic programs.

Summary

Metagenomi is a promising early-stage gene editing company with a unique metagenomics approach. Its strengths lie in its novel technology and strong IP portfolio, but it faces challenges related to early-stage development and competition from larger players. Successful development of its therapeutic programs and strategic partnerships are crucial for future growth. The company has a high potential, but also significant risks associated with biotechnology development.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Industry Reports
  • Analyst Reports

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may vary. Please consult with a financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Metagenomi, Inc. Common Stock

Exchange NASDAQ
Headquaters Emeryville, CA, United States
IPO Launch date 2024-02-09
Co-Founder, CEO & Chairman of the Board Dr. Brian Charles Thomas Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 176
Full time employees 176

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer. Metagenomi, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.